By Renaissance Capital, December 30, 2014 Link here. Nexvet, which is developing biologics for the treatment of pain and inflammation in cats and dogs, filed on Tuesday with the SEC to raise up to $60 million in an initial public offering. The Dublin, Ireland-based company, which was founded in 2010, plans to list on the NASDAQ […]
ITV Report link here. 22 December 2014 A physiotherapy service in Northamptonshire is giving people the chance to walk again with the world’s first self-supporting robotic exoskeleton. The device means people with mobility problems can move around without crutches or a walking frame. It’s got the backing of Winter Paralympic star Anna Turney who broke her back while snowboarding. […]
December 2014 – link here.
DUBLIN, Ireland; MELBOURNE, Australia –‐ December 3, 2014. Link here. Veterinary biologic therapy developer Nexvet Biopharma today announced the signing of a ten year collaboration and distribution agreement with Virbac (EPA:VIRP), one of the largest animal health dedicated companies in the world. Under the terms of the agreement, Virbac will distribute NV-01, Nexvet’s most advanced product, […]
4 November 2014. Link here. The update includes: – Work begins on the new fish oil refinery; – Strengthening the SeaDragon bench; – Food industry veteran joins the SeaDragon board; – The good oil – a word from SeaDragon Chief Executive, Ross Keeley. Contact Ross Keeley SeaDragon Chief Executive Officer Telephone: 03 547 0336
Link here. 2014 AIM WINNERS – Best Technology Award. Announced at the AIM Awards ceremony on 9 October 2014.
NZX & Media Release. Link here. 1 October 2014 SeaDragon strengthens leadership team to transition to Omega 3 production Permanent marketing, sales and finance appointments reflect SeaDragon growth and strong prospects New Zealand’s largest refiner and blender of high-quality fish oils SeaDragon today announced it has expanded its leadership team with the appointment of a permanent […]
DUBLIN, Ireland, MELBOURNE, Australia–‐ September 18, 2014. Link here. Veterinary biologic therapy developer Nexvet Biopharma today announced the appointments of Dr. Ashraf Hanna, M.D., Ph.D., and Dr. Joseph McCracken D.V.M., M.S., to its Board of Directors. Dr. Hanna is the Vice President of Commercial and Medical Affairs Finance at Genentech and Chief Financial Officer for the […]
15 September 2014. Posted in Pharma & Biopharma on 15 September, 2014. Nexvet Biopharma has added two former CSL (ASX:CSL) scientists to its veterinary biologics research team. CSL’s former director of preclinical cell biology, Dr Samantha Busfield, and former director of analytical biochemistry, Dr Dallas Hartman, have both joined Nexvet’s veterinary biologics research centre in Melbourne. The centre is designed […]
19 August 2014. Link here. The following resolutions were put to shareholders of SeaDragon Limited at its Annual Meeting held yesterday: 1. That Dr. Doug Wilson, retiring from office as Director of SeaDragon Limited by rotation, is re-elected as a Director of SeaDragon Limited; 2. That Mr. Jeremy Curnock Cook, retiring from office as Director of SeaDragon […]